Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for chemoprevention of prostate cancer

A prostate cancer and application technology, applied in the direction of pharmaceutical formulations, non-active ingredients of polymer compounds, medical preparations containing active ingredients, etc., can solve the concerns of patients and doctors, and the lack of methods for treating patients with prostate intraepithelial tumors, etc.

Inactive Publication Date: 2008-05-14
UNIV OF TENNESSEE RES FOUND
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, once PIN is diagnosed, standard healthcare necessitates more frequent biopsies and physical examinations
Plus, patients and doctors worry as prostate cancer diagnosis looms
Currently, there is no treatment for prostate intraepithelial neoplasia in patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for chemoprevention of prostate cancer
  • Method for chemoprevention of prostate cancer
  • Method for chemoprevention of prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0043] The preparation of pharmaceutical compositions containing active ingredients is known in the art. Typically, such compositions are prepared as an aerosol of the polypeptide for administration to the nasopharynx, or as injectable solutions or suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The formulation may be emulsified. The active therapeutic ingredient is usually mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, etc. and combinations thereof. In addition, the composition, if desired, can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, which enhance the effectiveness of the active ingredients.

[0044] The active ingredients can be formulated into compositions in the form of neutral pharmaceutically...

Embodiment 1

[0055] Example 1: Transgenic adenocarcinoma mouse prostate

[0056] Research on prostate cancer chemoprevention is hampered by a lack of suitable animal models. The recently developed transgenic adenocarcinoma mouse prostate (TRAMP) model has enabled the study of chemoprevention. In the TRAMP model described in Greenberg et al., Prostate cancer in a transgenic mouse, Proc.Natl Acad.Sci.USA, 1995, Vol.92, 3439-3443 pages, the PB-SV40 large T antigen (PB-Tag) transgene is in Specifically expressed in mouse prostate epithelial cells. The results show that this model has several advantages over existing models: 1) mice develop progressive prostatic epithelial hyperplasia at 10 weeks of age and invasive adenocarcinoma at about 18 weeks of age; 2) metastatic spread of prostate cancer The pattern mimics human prostate cancer, and the common metastatic sites are lymph nodes, lungs, kidneys, adrenal glands, and bones; 3) The occurrence and progression of prostate cancer can occur wit...

Embodiment 2

[0062] Example 2: Immunohistochemical data analysis

[0063] Microscopic images of each tissue section were evaluated by computer-aided (Mac 9500-I 32 computer and monitor) image quantification (NIH-Image 1.6PPC) with a Kodak DCS 460 camera on a Nikon Microphot-FX microscope, and were evaluated by using Quantification was obtained by color-assisted quantification system image analysis (IPLab Spectrum 3.1, Scanalytics, Inc., VA) that distinguishes color differences in stained tissue sections. Thresholds were set to identify various tissue components of the prostate. For each full screen of a color monitor, the area pixel density corresponding to each of these tissue components is calculated. A total of 5 screens per prostate section were averaged. Immunohistochemical images can be digitized and quantified, enabling statistical evaluation by determining correlation coefficients and probabilities (2-tailed) of samples.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to uses of antiestrogen in the medicine preparation. The medicine is used for preventing, limiting and restraining the prostatic cancer or potential prostatic cancer, and for decreasing the danger of prostatic cancer or potential prostatic cancer, or curing the prostatic cancer or potential prostatic cancer, wherein, the antiestrogen is Toremifene, Raloxifene, Tamoxifen, Idoxifene or Droloxifene.

Description

[0001] This application is a divisional application of the Chinese patent application 00818228.0 filed on November 8, 2000, with the title of invention "Method for Prostate Cancer Chemoprevention". technical field [0002] The present invention relates to the chemoprevention of prostate cancer, and more particularly to methods of deterring or inhibiting latent prostate cancer comprising administering chemopreventive drugs and their analogs and metabolites to mammals. The chemopreventive drug prevents prostate cancer, prevents recurrence of prostate cancer, curbs or inhibits the occurrence of prostate cancer; and treats prostate cancer. Background technique [0003] Prostate cancer is one of the most commonly occurring cancers among Americans, with hundreds of thousands of new cases diagnosed each year. Unfortunately, more than 60% of newly diagnosed prostate cancer cases are found to be pathologically progressive, incurable and have a poor prognosis. One way to address this...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/015A61K31/138A61K31/4535A61K31/565A61P35/00A61K9/06A61K9/08A61K9/10A61K9/107A61K9/127A61K9/14A61K9/20A61K9/48A61K31/00A61K45/00A61K47/26A61K47/36A61K47/38A61K47/40A61P5/32A61P43/00
CPCA61K31/4535A61K45/06A61K31/00A61K31/138A61K31/565A61K31/015
Inventor 米切尔·S·施泰纳沙兰·拉高
Owner UNIV OF TENNESSEE RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com